Key result
Sacubitril/valsartan transforms HF management by shifting from neurohormonal antagonism to neurohormonal modulation.
Combined RAAS and NEP inhibition with sacubitril/valsartan represents a major breakthrough in heart failure management.
Answers are grounded in this paper and cite their sources.
May guide ARNI use in eligible HF patients; leaves open optimal selection and long-term safety via prospective trials.
The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), and beta-blockers. Combined NEP and ACE blockade although unsuccessful with omapatrilat in the OVERTURE trial, found success with sacubitril/valsartan in the Paradigm-HF trial. The results of PARADIGM-HF trial represent one of the most significant breakthroughs in the management of HF of the last decade, representing a shift from neurohomonal antagonism to neurohormonal modulation.
No takes yet. Share an insight, caveat, or question.
Vergaro et al. (2019) conducted a review in Heart Failure. Combined RAAS and NEP Inhibition was evaluated. Combined NEP and ACE blockade with sacubitril/valsartan represents a significant breakthrough in the management of heart failure, shifting from neurohormonal antagonism to neurohormonal modulation.
Synapse has enriched 10 related papers. Consider them for comparative context: